collecting links from twitter
← Back to all posts
Thread (21 posts)
Adenovirus genomes are compact but busy. In human serotype 5, the workhorse of most adenoviral vector programs, about 36kb of linear, double-stranded DNA encodes three timed sets of genes: early (E1A/B, E2, E3, E4), intermediate (IX, IVa2) and late (L1-L5) (x). In brief summary, E1A turns on the rest, E2 supplies the replication enzymes, E3 modulates host immunity, and the late genes build the capsid and finish assembly.
Can you unpack and contextualize
Claude 4 Sonnet (T) via @hdevalence.bsky.social
Thinking Summary
The user is asking me to unpack and contextualize a specific quote from the embedded article about adenoviral vectors. The quote describes the organization of adenoviral genomes, specifically focusing on how adenovirus serotype 5 (Ad5) organizes its genes into temporal expression classes. Let me break this down: 1. The basic structure: 36kb linear double-stranded DNA 2. Three temporal gene expression classes: - Early genes (E1A/B, E2, E3, E4) - Intermediate genes (IX, IVa2) - Late genes (L1-L5) 3. The functions of each class I should contextualize this within: - Why this temporal organization matters for viral replication - How this relates to vector engineering (which genes can be deleted) - Why this creates manufacturing challenges - How this compares to other viral vectors like AAV This is a technical topic so I should explain it clearly but with appropriate depth.
This passage describes the sophisticated temporal gene expression program that makes adenoviruses both powerful and challenging as gene therapy vectors. Let me break down what's happening here:
The Temporal Cascade
Adenoviruses orchestrate their replication through a carefully timed genetic program, like a molecular assembly line:
Early genes (E1-E4) fire first after infection:
- E1A: The master switch - turns on all other viral genes and pushes the host cell into S-phase for DNA replication
- E1B: Works with E1A to overcome cellular apoptosis and tumor suppressor responses
- E2: Provides the DNA replication machinery (DNA polymerase, DNA binding protein, etc.)
- E3: Immune evasion toolkit - helps the virus hide from host immune responses
- E4: Fine-tunes replication and helps with late gene expression
Intermediate genes (IX, IVa2) bridge the transition to late phase, helping with DNA packaging and capsid assembly.
Late genes (L1-L5) encode the structural components - all the proteins needed to build new viral particles.
Why This Matters for Gene Therapy
This temporal organization creates both opportunities and headaches:
The Good: The modular design means you can delete entire gene cassettes (like E1 and E3) to make room for therapeutic cargo while still maintaining viral function - if you provide the missing functions elsewhere.
The Bad: Every gene you delete requires compensating infrastructure:
- Delete E1? Need special packaging cell lines that express E1 proteins
- Delete E2 or E4? Need even more complex cell lines
- This is why vector manufacturing gets progressively more difficult with each "generation"
The Manufacturing Tax
Compare this to AAV, which has a much simpler genome (~4.7kb vs 36kb) with just a few genes. AAV's simplicity means:
- Easier to clone and manipulate
- Higher transformation efficiency
- More predictable production yields
- Simpler quality control
Adenovirus's complexity means that even basic molecular biology steps (cloning, transfection, amplification) become bottlenecks. The passage mentions that only 1 in 600 million adenoviral genomes successfully produces infectious virus in standard protocols - that's the "manufacturing tax" of complexity.
This is why, despite adenovirus's 7x larger cargo capacity, the field has gravitated toward AAV for most applications. The question is whether recent advances in manufacturing and engineering can finally make that cargo space worth the complexity cost.
can you be more precise about exactly what point constitutes “infection” and how the described phases connect to that? ie expand those phases into an end to end timeline
Claude 4 Sonnet (T) via @hdevalence.bsky.social
Thinking Summary
The user wants me to be more precise about the timeline of adenoviral infection, specifically when "infection" starts and how the temporal phases connect to create an end-to-end timeline. Let me think through the adenoviral lifecycle step by step: 1. Initial binding and entry 2. Nuclear entry and uncoating 3. Early gene expression (immediate early vs delayed early) 4. DNA replication 5. Late gene expression 6. Assembly and release I need to be precise about what constitutes "infection" - is it binding? Entry? Nuclear delivery? First gene expression? And then map out the temporal cascade with actual timing where possible.
Great question - let me map out the precise adenoviral infection timeline:
Phase 0: Entry (0-2 hours post-infection)
"Infection" begins when the virus binds to cellular receptors (CAR for Ad5), triggers endocytosis, escapes the endosome, and delivers its genome to the nucleus. The viral DNA remains as an episome - it doesn't integrate into the host chromosome.
Phase 1: Immediate Early (2-6 hours post-infection)
- E1A expression starts immediately - this is the first viral gene transcribed
- E1A protein accumulates and begins activating other viral promoters
- E1A also pushes the quiescent cell into S-phase by inactivating Rb protein
- This is when the cell's fate is sealed - E1A expression commits it to supporting viral replication
Phase 2: Delayed Early (6-12 hours post-infection)
- E1B comes online to suppress p53-mediated apoptosis (cells would otherwise kill themselves when forced into S-phase)
- E2 genes activate, producing DNA replication machinery
- E3 genes express immune evasion proteins
- E4 genes begin low-level expression
- The cell is now fully reprogrammed as a viral factory
Phase 3: DNA Replication (8-24 hours post-infection)
- Viral DNA replication begins around 8 hours
- This is driven by the E2-encoded replication proteins
- DNA synthesis continues for ~16 hours
- Viral genome copy number increases dramatically
Phase 4: Late Gene Expression (12-36 hours post-infection)
- Late genes (L1-L5) ramp up as DNA replication peaks
- These encode all structural proteins: hexon, penton, fiber, etc.
- E4 expression also peaks, helping optimize late gene expression
- Massive amounts of capsid proteins are produced
Phase 5: Assembly and Lysis (24-48 hours post-infection)
- Viral genomes get packaged into capsids in the nucleus
- Mature virions accumulate
- Cell eventually lyses, releasing 10,000-100,000 new viral particles
Key Temporal Control Points
The transition from early to late phases is triggered by DNA replication initiation around 8 hours. This acts as the molecular switch - before replication, early genes dominate; after replication begins, late genes take over.
For gene therapy vectors, this timeline explains why different generations have different problems:
- 1st gen (E1/E3 deleted): Late genes still express at low levels → ongoing immunogenicity
- 2nd gen (additional deletions): Disrupted temporal cascade → manufacturing problems
- 3rd gen (gutless): No viral genes at all → minimal immunogenicity but needs helper virus
The manufacturing challenges stem from trying to recreate this precisely timed, interdependent cascade in cell culture while missing key regulatory components.
can you elaborate on what the article means when referring to “leaky gene expression” after changing E1?
Claude 4 Sonnet (T) via @hdevalence.bsky.social
Thinking Summary
The user is asking about "leaky gene expression" in the context of E1-deleted adenoviral vectors. Let me think through what's happening here. When you delete E1 from an adenoviral vector, the goal is to make it replication-defective. E1A is the master regulatory protein that turns on the entire adenoviral gene expression program. So in theory, if you delete E1, the vector shouldn't be able to express any other viral genes and should just deliver its therapeutic cargo without producing viral proteins that would trigger immune responses. However, the article mentions that in practice, there's still "leaky" expression of remaining viral genes, particularly late genes, even without E1. This happens because: 1. Host cells have their own transcription factors that can sometimes activate viral promoters 2. The viral genome still contains all the promoter sequences for the other genes 3. These promoters weren't evolved to be completely dependent on E1A - they can be activated at low levels by cellular factors This is problematic because: - Late genes encode capsid proteins - Expression of these viral proteins triggers immune responses - This defeats part of the purpose of deleting E1 in the first place The article mentions this contributes to the immunogenicity of first-generation vectors, beyond just the initial immune response to the capsid proteins from the original infection.
The "leaky gene expression" issue gets to the heart of why first-generation adenoviral vectors aren't as clean as we'd like them to be.
The Theory vs. Reality
The Plan: Delete E1A (the master switch) → no viral gene expression → vector just delivers cargo and stays quiet → reduced immunogenicity
What Actually Happens: Even without E1A, other viral genes still get expressed at low levels, particularly the late genes that encode capsid proteins.
Why This Leakiness Occurs
E1A is the primary activator of viral gene expression, but the viral promoters aren't completely dependent on it. Here's what's happening:
-
Cellular transcription factors: The host cell contains transcription factors that can weakly activate viral promoters. These weren't the intended activators, but molecular biology is messy - promoters often respond to multiple signals.
-
Promoter promiscuity: Viral promoters evolved to be responsive to cellular conditions that indicate good replication opportunities. Some of these cellular signals are present even without E1A.
-
Chromatin context: When the viral DNA enters the nucleus, it doesn't immediately get packaged into repressive chromatin. During this window, cellular machinery can access and transcribe from viral promoters.
Why This Matters
The leaky expression is particularly problematic because:
- Late genes = capsid proteins: The "leaky" genes are often the late genes (L1-L5) that encode structural proteins like hexon, penton, and fiber
- MHC presentation: These viral proteins get processed and presented on MHC class I molecules, marking the cell as "infected"
- T-cell activation: This triggers adaptive immune responses against the transduced cells
- Persistent antigen: Unlike a normal infection that's cleared, these vector-transduced cells keep leaking viral proteins over time
The Immunological Consequence
This creates a two-hit immune problem:
- Immediate: Innate immune response to the viral capsid and DNA
- Delayed: Adaptive immune response to the leaked viral proteins being presented on transduced cells
This is why even "replication-defective" first-generation vectors still provoke substantial immune responses, and why the field moved toward gutless vectors that remove nearly all viral coding sequences. The goal is to get down to just the therapeutic cargo with minimal viral "noise" that could trigger immunity.
It's a reminder that in virology, "turning off" a genetic program is much harder than turning it on - evolution built these systems to be robust, not easily silenced.